posted
Q, I dont know what you think your seeing but i have three L2s screens and none will show me how many shares a MM has just that he is there and most of the time it says 50 are 2500 are 1500, but they can sit all day if they have the shares, thats why i like seeing them jump around thats good sitting thats bad.
IP: Logged |
posted
I am holding TWOG OMOG AMEP CLBE PMED. When can I expect these to grow? I'm holding these for the long term...
Posts: 112 | From: Syracuse, NY | Registered: Oct 2005
| IP: Logged |
CLBE: up 21%; news expected next week. VTLV: up 13%; quarter report expected next week. VMHVF: up 10%; news expected next week. PMED: down 12%; great entry point.
Posts: 3228 | From: Michigan | Registered: Aug 2005
| IP: Logged |
posted
nice close all,at least they did not sell a block after hours and that is a good sign,it may actually be over.News is overdue now so we should get a PR early next week and the quartery is due within 3 weeks now.
everyone have a great and safe weekend and lets look forward to a great November starting Tuesday!
posted
Doctors: Adult stem cells, cord blood hold most promise By Jim Shea Correspondent
At the 18th bi-annual interfaith Breakfast for Life Oct. 26 at Rutgers University, New Brunswick, approximately 150 doctors, students, clergy, members of the professional community and other pro-life advocates heard from one of the leading experts on the topic of ethics and stem cell research.
Speaker Dr. David Prentice is a founding member of Do No Harm: The Coalition of Americans for Research Ethics and a fellow of the Wilberforce Forum Council for Biotechnology Policy, both in Washington, D.C., and an advisory board member for the Institute on Biotechnology and the Human Future, Chicago.
“We keep hearing about the promise of embryonic stem cells, but the claims are simply unsubstantiated,” he said. “At this point in time there is little evidence of the effectiveness of embryonic stem cells. Proponents have yet to take even one dish of embryonic stem cells and have these cells change into one specific cell, i.e. a heart cell or brain cell. Based on experiments to date, it’s not safe to even try and apply them to patients.
“The bottom line,” continued Dr. Prentice, “is that our real promise lies not in the use of embryonic stem cells but with adult stem cells. Adult stem cells are today already at work in patients. I can document, through published scientific papers, with over 65 human diseases, where patients are better already, having been effectively treated through adult stem cells.”
“Some scientists admit there are ethical concerns in the use of embryonic stem cells,” Dr. Prentice said. “But, these same scientists continue to ignore the success in patients and the use of adult stem cells. The debate is ongoing. We face a lot of challenges, but the key question remains, ‘What does it mean to be human, and what kind of values do we give to any human life, whether it be a little embryo, a fetus in the womb, a newborn or someone at the other end of their life with advanced Alzheimer’s?’
“We must value every human life,” he added. “We need to push ethical science. We have an ethical problem in one sense, to make sure that everyone knows the real facts about the stem cell debate. The ethical question is that you have to kill a human embryo, a young human life, in order to obtain an embryonic stem cell. What we are dealing with is a human being at its earliest stage of life. We need to make sure we know the full facts and get out and talk about them with our friends, family and people at work. We have to write letters to the editor and to our legislators.”
Dr. Prentice also referred to a push in the U.S. Senate for a national cord blood bank, “Where we can do the kinds of magic we need to do in order to treat patients. There are thousands of patients already better, thanks to the use of cord blood alone.”
“Yesterday, (Oct. 18) Acting Gov. Richard Codey signed an executive order to establish a cord blood bank for umbilical cord blood,” said Marie Tasy, executive director of New Jersey Right to Life, adding to Dr. Prentice’s comments. “Umbilical cord blood is ethical stem cell research, and is already providing cures for people with sickle cell anemia and leukemia.”
Tasy also discussed issues that could be addressed by the legislature after the November election. “One would use $150 million in funds to construct the New Jersey Stem Cell Institute in New Brunswick,” she said. “There are also two legislative measures that would place a question on the ballot to have voters approve millions of dollars in public bond money. One measure would use $230 million and the other calls for $500 million.”
Fellow guest speaker Dr. Gary Friedman, medical director of the Center for Regenerative Medicine, Morristown Memorial Hospital, and trustee for the New Jersey Stem Cell Research and Education Foundation, agreed with Dr. Prentice’s assessment. “As of 6 p.m. last night, there were over 141 approvals for human clinical trials, utilizing human umbilical cord stem cells,” he said. “Going back 10 or 15 years, there were probably only five or 10 such cases. At the current rate, use of adult stem cells is exploding.”
“What I have learned,” Dr. Friedman said, “is that life is precious. I get to see people giving life to other people, day in, day out. People volunteer to donate their organs to a friend or family member. This shows the great giving capacity of human beings. We also understand, through the process of arranging for organ transplants, that we cannot forcibly take a life from another human being.”
Those who attended the breakfast felt it provided them with vital information that often isn’t discussed in regard to stem cell research.
“I didn’t know how effective adult stem cell research was,” said Nicole Czarnecki, a Rutgers University student. “I had no idea adult stem cells worked so well and that embryonic stem cells were not as effective.”
Shannon Varga, a student from St. Peter the Apostle High School, New Brunswick, expressed gratitude for the opportunity to attend the breakfast.
“I’m so glad I came today, to find out the importance of adult stem cell research,” she said. “I’m convinced embryonic stem cell research is wrong.”
CAMDEN Acting Gov. Richard J. Codey and Democratic gubernatorial candidate Sen. Jon Corzine reaffirmed their support for stem-cell research Thursday afternoon with a tour of the Coriell Institute for Medical Research.
"It's essential that public policy be supportive of stem-cell research in all of its forms," Corzine said. "This is fundamental for our state and all of mankind."
Codey has begun a series of initiatives to fund stem-cell research. Last week, he named Coriell, in Camden, as one of two public umbilical cord and placental blood banks in the state.
The stem cells are harvested from the blood in placentas and umbilical cords that would be discarded after a normal birth.
The institute stores the stem cells, which are made available to researchers looking to cure diseases like diabetes, AIDS, multiple sclerosis, Parkinson's and Alzheimer's.
Stem cells can also take the place of bone marrow in transplants for people with leukemia and sickle-cell anemia. Since last week's announcement, the institute has already received two placenta donations, Codey said.
"Hopefully, some human being will have their life saved by that placenta," Codey said.
Republican candidate Doug Forrester has said he said he favors adult stem-cell research but does not support research on embryonic stem cells.
As the second state to legalize embryonic stem-cell research, New Jersey must remain a leader in the biomedical research, Corzine and Codey said.
For the Liebermans, a Mount Laurel family of four, the issue is personal. "It's about me getting well," said Barbara Lieberman, who has suffered from multiple sclerosis since 1985. "My kids, they don't understand why it's not being funded, why cells have more rights than their mom."
The children were so outraged that they decided to do something about it.
Ten-year-old Ellie Lieberman, a fifth-grader at the Hartford School, raised thousands of dollars for the National Multiple Sclerosis Society selling "garden goodies" -- mostly plants, seeds and decorative bricks made by her 12-year-old brother Ben.
Scientists should focus on proven adult stem-cell research
JESSICA RODGERS
October 30, 2005
One of my favorite television shows is the science-fiction drama "Stargate Atlantis," mainly because of its smart writing and fast-paced action. A recent episode, however, reminded me of the distortion of facts surrounding a current and real issue.
The writers were talking about stem cells. Embryonic stem cells, to be exact.
Before I continue, allow me to give a summary of what stem cells are, and why they are considered to be so valuable. In the case of embryonic stem cells, they are taken from a 5- to 7-day-old embryo. In adult bodies, cells have specific jobs -- blood cells, brain cells, skin cells, etc. However, in an embryo, these systems are not finished developing and easily can be given a different purpose by scientists.
Many scientists think that they can use this to their advantage by taking the cells and shaping them into whatever may be needed for any given treatment. Great numbers of people, myself included, see a huge moral issue with this, however. The cells cannot be harvested without the destruction of a growing baby. A small baby, yes, but it cannot be confused with anything else. It is not a baby fish or a baby cat; it is, inarguably, a baby human.
All moral issues aside, though, the fact is that embryonic stem cells, for all the hype surrounding them, offer no benefits. Not one single treatment, much less a cure, has come from these studies. There haven't even been human tests with them.
Conversely, adult stem cells have provided more than 100 types of treatment for diseases, including numerous types of cancer, leukemia, multiple sclerosis and Parkinson's disease. That is only a small sampling of what adult stem cells have been able to treat with success.
It seems that it should be a common-sense issue that we invest our research dollars into a study that has real promise, not one that is a flop. Shouldn't all of our resources be going toward a study that can treat dying people?
The science behind adult stem cells is similar to that of embryonic cells. Yes, the cells already have specified "jobs," but researchers are able to simply take the cells and change their purpose. Even better, by using adult stem cells, patients receive cells from their own body, taking away the risk of reacting to a separate DNA pattern -- a risk that is real with stem cells from embryos.
President Bush has received much criticism for his policies regarding embryonic-stem-cell research, but unfortunately, those who favor using those cells are woefully misinformed of the truth. The truth is, as science has discovered, embryonic stem cells simply don't work. In many cases, they can make a situation worse by taking on the characteristics of cancerous cells. As someone who has experienced cancer in my family, I find that to be no small risk.
What with the moral issues, scientific problems and health risks involved in using embryonic cells, there is no need to hold out hope for what these cells could do for our future. Scientists already have a solution that is producing real results in the treatment of diseases. With adult stem cells, the future is now.
Jessica Rodgers, 16, is a home-schooled senior. Reach her through education reporter Sarah Evans at sevans*StatesmanJournal.com or (503) 399-6856.
although this PR is focused more on embryonic stem cells the unethical and controversal method is being pushed aside for a better method of adult stem cell usage.
October 30, 2005
Scientists turn stem cells into cancer killers Research on federally approved embryonic line offers hope of creating tumor treatment
By David Shaffer Minneapolis Star Tribune MINNEAPOLIS, Minn. -- University of Minnesota researchers have turned embryonic stem cells into cancer-fighting cells in the lab. The research at the Stem Cell Institute doesn't offer an immediate cancer treatment, but the findings suggest that stem cells eventually could be used to boost the body's ability to fight tumors.
Using one of the federally approved embryonic stem cell lines, scientists first coaxed the cells to turn into blood cells, including "natural killer cells." These naturally occurring cells produce proteins that attack tumors. Then the research team mixed the killer cells with cancer cells in a culture dish and watched as the cancer cells died, according to a report in the Journal of Immunology. "This is really the first evidence that we can harness human embryonic stem cells to make a cell population that is able to kill tumor cells," said Dr. Dan Kaufman, an assistant professor at the institute and co-author of the report. Researchers next plan to test whether stem cell-derived killer cells will attack tumors in mice, he said. Similar studies elsewhere using adult stem cells have successfully attacked cancer cells in lab animals, Kaufman said. In theory, boosting the body's natural killer cells should help battle cancers. It remains unclear whether adult or embryonic stems cells will be more promising in such efforts. Kaufman said researchers eventually may be able to target natural killer cells to attack tumor cells. For that to work, more embryonic cell lines may be needed, he said. Government rules now limit the number of such stem cell lines available for federally funded research.
posted
October 27, 2005 Ethicists Say New Stem Cell Study Deserves Closer Look WASHINGTON (BP)–One of two new techniques aimed at producing stem cells without harming a human embryo is worthy of further study through research on animals, some pro-life bioethicists are cautiously saying. In one study, a team from the Massachusetts Institute of Technology used a version of cloning known as altered nuclear transfer (ANT). In the process, a gene in a mouse skin cell is turned off before the nucleus is placed in a fertilized egg, which develops to a stage in which stem cells can be extracted. By switching off the gene, however, the researchers make the embryo incapable of implantation in the uterus. The question in this procedure appears to be whether an embryo has truly been produced.
Pro-life bioethicists are not as inclined to endorse another new method reported on by a team from Advanced Cell Technology in Worchester, Mass. The researchers took single cells from eight-cell mouse embryos. They derived stem cell lines from those individual cells, and the embryos seemingly developed into healthy mice. The procedure is similar to preimplantation genetic diagnosis (PGD), a technique utilized in in vitro fertilization. In PGD, an individual cell is removed from an eight-cell embryo for genetic testing before the tiny human being is implanted.
The new techniques were outlined Oct. 16 in the online version of Nature, a science journal.
(see Calbatechs new extraction techniques)
While some ethicists said both methods pass ethical scrutiny, others who have led the opposition to destructive embryonic research offered qualified support only for experiments using the ANT technique.
“The quest for ethical ways to retrieve stem cells is genuinely encouraging, and animal studies should certainly go forward expeditiously,” bioethicist C. Ben Mitchell told Baptist Press, “but it’s too early to tell whether the [ANT] technique can be applied to human embryos without harm to the embryos. We should remain open to the possibility.”
Even so, one thing that must be avoided “is the view that human beings – whether embryos or adults – are natural resources we can strip mine,” said Mitchell, associate professor of bioethics at Trinity Evangelical Divinity School in suburban Chicago and a consultant for the Southern Baptist Ethics & Religious Liberty Commission. “Human beings deserve respect, not commodification.”
There were questions about each of the methods from two members of the President’s Council on Bioethics.
William Hurlbut, a consulting professor at Stanford University and a proponent of the ANT technique, told Nature concerning the PGD-like method that removes a single cell, “You are getting a live birth, but are you getting the same child you would otherwise get? It is uncomfortable to me to endorse such a strategy.”
posted
just lurking on a few other boards and ran across some interesting post.
concerning adult stem cells and extract by: nobodysfool62 Long-Term Sentiment: Strong Buy 10/30/05 08:10 am Msg: 283950 of 284028
Although I no longer hold GERN I do own STEM and ASTM but after some serious and indepth DD and checking many varibles including current PPS compared to potential PPS I believe CLBE is by far the best investment in this sector now.Dig thru the 10-K and look at the rev increase that will be even higher this quarter and are expected to close this year profitable,its obvious that the current entry price will not last much longer.With 3 patents pending,FDA approval for new extraction methods and they even have their own division for stem cell banking.All this just from one division and does not include the DNA and molecular R&D divisions.I feel quite confident CLBE and its divisions will be measure in dollars per share in the very near future,your simple DD will uncover this.
With the rate of blood diseases such as leukaemia or thalassemia increasing among the Thai population, Thai Life Insurance is now offering coverage for stem cell therapy treatments.
According to Preedee Kwan-ngam, an executive vice-president, the new plan is the first of its kind in the world, covering medical expenses for stem cell transplants.
Stem cells are cells that have the potential to develop into many different cell types in the body.
The ethics of using stem cells for research have been hotly debated as most are found at the embryonic stage. To avoid controversy, some scientists have turned to studying adult stem cells derived from blood and bones.
In Thailand, the best known case of the benefits of stem cell technology is that of Dokrak Pethprasert, a 47-year-old woman,who had a limbal stem cell transplant after going blind following treatment at a hospital.
According to Mr Preedee, the new stem cell treatment will be available as an added rider to existing health insurance policies under the Health Insurance Plus Plan.
The coverage will not include cosmetic surgery and physical rehabilitation.
Due to be introduced on Dec 1, the coverage will be available under seven plans with the amounts insured ranging from 300,000 to one million baht.
The annual premium for 300,000 baht in coverage, for instance, will be around 2,700 baht for men and 3,400 baht for women.The coverage is available for those aged from one month to 65 years.
posted
I think we are starting to begin the reversal and uptrending now,hopefully we get back to where CLBE normally traded at .20 to .25 and don't forget the 10-Q will be out very soon (around the 16th)and we should get a completely new view of where this puppy is heading!
this stock will be trading over a dollar within 6 months.
also from another board.
CLBE-major biotech play coming by: wickedclownicp2003 Long-Term Sentiment: Buy 10/31/05 09:56 am Msg: 1178939 of 1178970
remember buying BIPH at .09? Now try CLBE under .05,from last 10-k they expect to be profitable this year,the 10-q is due around the 16th.They are into Adult stem cell research and also molecular and DNA R&D.Just chart it and you will see that its heading back to .20 to .25 on current fundamentals. Analyst project this to hit $1 to $1.20 within 6 to 12 months.DD it and you will see why they are projecting that figure!OS at 39mill.
posted
Quest- do you think this will retrace again, or is .51 a good place to buy some more?
Posts: 112 | From: Syracuse, NY | Registered: Oct 2005
| IP: Logged |
posted
trader--thats a decision you need to make,it could retrace after lunch or it could blast off to .08 since theres little resistance between there and here.If you are holding this mid to long term you will see that anywhere under a dime now is a great opportunity.
posted
Adult stem cell news and info really getting noticed,heres another penny stem cell stock,soon we will be right there with them imo.
BrainStorm Announces Significant Preclinical Benefit of Its GDNF Producing Stem Cells in Animal Models of Parkinson's 10/31/2005 9:00:00 AM EST
BrainStorm Cell Therapeutics (OTCBB:BCLI), today announced that the company's scientific collaborators at Tel Aviv University had successfully implanted human bone marrow derived stem cells into animal models of Parkinson's disease and observed improved motor function within just two weeks of implantation. The beneficial effect was retained for over three months. Worldwide rights to the development and commercialization of the new technology are exclusively licensed to BrainStorm.
The differentiated cells were previously shown to produce a unique protein required for brain cell survival and growth, glial cell line derived neurotrophic factor (GDNF). The GDNF expressing cells, known as astrocytes, were derived by differentiation of human bone marrow stem cells, using the proprietary NurOwn(TM) technology that has been developed by the Company based on discoveries made by Prof. Eldad Melamed and Dr. Daniel Offen of Tel-Aviv University. This technology is exclusively licensed to the Company. In the current study, the cells were transplanted into Parkinson's disease rats, generated by specifically damaging their dopaminergic cells. Within weeks of the transplantation, there was significant improvement in their characteristic disease behavior, including more than 50% reduction in rotational movement and enhancement in their paw reaching capacity.
GDNF capacity to protect a variety of neurons and induce neural sprouting holds great promise for treatment of many neurodegenerative diseases, including Parkinson's disease, Amyotrophic Lateral Sclerosis (ALS), Multiple Sclerosis (MS), Spinal Cord Injury (SCI) and even Alzheimer's disease. GDNF has been shown efficacious in restoration of neural function in multiple disease models and its use for human disease is currently being evaluated in clinical trials.
Unfortunately the delivery of GDNF to the disease site is difficult. GDNF is a protein and, as such, has limited stability and brain penetration. Attempts made to deliver the protein directly into the brain have met with limited success. An alternative approach, to deliver GDNF by genetic therapy, suffers the limitations and risks of using viral vectors. Moreover, cell therapeutic approach using either genetically engineered or differentiated embryonic and neural stem cells are limited by issues of graft rejection and potential tumorogenic risk.
UBBFriend: Email this page to someone!
Printer-friendly view of this topic
![[Big Grin]](biggrin.gif)
